Recent developments in neurofibromatoses and RASopathies: Management, diagnosis and current and future therapeutic avenues

Katherine A. Rauen, Susan M. Huson, Emma Burkitt-Wright, D. Gareth Evans, Said Farschtschi, Rosalie E. Ferner, David H. Gutmann, C. Oliver Hanemann, Bronwyn Kerr, Eric Legius, Luis F. Parada, Michael Patton, Juha Peltonen, Nancy Ratner, Vincent M. Riccardi, Thijs van der Vaart, Miikka Vikkula, David H. Viskochil, Martin Zenker, Meena Upadhyaya

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Neurofibromatosis type 1 (NF1) was the first RASopathy and is now one of many RASopathies that are caused by germline mutations in genes that encode components of the Ras/mitogen-activated protein kinase (MAPK) pathway. Their common underlying pathogenetic etiology causes significant overlap in phenotypic features which includes craniofacial dysmorphology, cardiac, cutaneous, musculoskeletal, GI and ocular abnormalities, and a predisposition to cancer. The proceedings from the symposium "Recent Developments in Neurofibromatoses (NF) and RASopathies: Management, Diagnosis and Current and Future Therapeutic Avenues" chronicle this timely and topical clinical translational research symposium. The overarching goal was to bring together clinicians, basic scientists, physician-scientists, advocate leaders, trainees, students and individuals with Ras pathway syndromes to discuss the most state-of-the-art basic science and clinical issues in an effort to spark collaborations directed towards the best practices and therapies for individuals with RASopathies.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalAmerican Journal of Medical Genetics, Part A
Volume167
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Neurofibromatoses
Musculoskeletal Abnormalities
Skin Abnormalities
Eye Abnormalities
Gene Components
Neurofibromatosis 1
Translational Medical Research
Germ-Line Mutation
Mitogen-Activated Protein Kinases
Practice Guidelines
Students
Physicians
Therapeutics
Neoplasms

Keywords

  • Capillary malformation-AV malformation syndrome
  • Cardio-facio-cutaneous syndrome
  • Costello syndrome
  • Legius syndrome
  • Neurofibromatosis
  • Noonan syndrome
  • Ras/MAPK
  • RASopathy
  • Signal transduction pathway
  • Therapy

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Rauen, K. A., Huson, S. M., Burkitt-Wright, E., Evans, D. G., Farschtschi, S., Ferner, R. E., ... Upadhyaya, M. (2015). Recent developments in neurofibromatoses and RASopathies: Management, diagnosis and current and future therapeutic avenues. American Journal of Medical Genetics, Part A, 167(1), 1-10. https://doi.org/10.1002/ajmg.a.36793

Recent developments in neurofibromatoses and RASopathies : Management, diagnosis and current and future therapeutic avenues. / Rauen, Katherine A.; Huson, Susan M.; Burkitt-Wright, Emma; Evans, D. Gareth; Farschtschi, Said; Ferner, Rosalie E.; Gutmann, David H.; Hanemann, C. Oliver; Kerr, Bronwyn; Legius, Eric; Parada, Luis F.; Patton, Michael; Peltonen, Juha; Ratner, Nancy; Riccardi, Vincent M.; van der Vaart, Thijs; Vikkula, Miikka; Viskochil, David H.; Zenker, Martin; Upadhyaya, Meena.

In: American Journal of Medical Genetics, Part A, Vol. 167, No. 1, 01.01.2015, p. 1-10.

Research output: Contribution to journalArticle

Rauen, KA, Huson, SM, Burkitt-Wright, E, Evans, DG, Farschtschi, S, Ferner, RE, Gutmann, DH, Hanemann, CO, Kerr, B, Legius, E, Parada, LF, Patton, M, Peltonen, J, Ratner, N, Riccardi, VM, van der Vaart, T, Vikkula, M, Viskochil, DH, Zenker, M & Upadhyaya, M 2015, 'Recent developments in neurofibromatoses and RASopathies: Management, diagnosis and current and future therapeutic avenues', American Journal of Medical Genetics, Part A, vol. 167, no. 1, pp. 1-10. https://doi.org/10.1002/ajmg.a.36793
Rauen, Katherine A. ; Huson, Susan M. ; Burkitt-Wright, Emma ; Evans, D. Gareth ; Farschtschi, Said ; Ferner, Rosalie E. ; Gutmann, David H. ; Hanemann, C. Oliver ; Kerr, Bronwyn ; Legius, Eric ; Parada, Luis F. ; Patton, Michael ; Peltonen, Juha ; Ratner, Nancy ; Riccardi, Vincent M. ; van der Vaart, Thijs ; Vikkula, Miikka ; Viskochil, David H. ; Zenker, Martin ; Upadhyaya, Meena. / Recent developments in neurofibromatoses and RASopathies : Management, diagnosis and current and future therapeutic avenues. In: American Journal of Medical Genetics, Part A. 2015 ; Vol. 167, No. 1. pp. 1-10.
@article{8d51880628b54e8485e9c608498b16d6,
title = "Recent developments in neurofibromatoses and RASopathies: Management, diagnosis and current and future therapeutic avenues",
abstract = "Neurofibromatosis type 1 (NF1) was the first RASopathy and is now one of many RASopathies that are caused by germline mutations in genes that encode components of the Ras/mitogen-activated protein kinase (MAPK) pathway. Their common underlying pathogenetic etiology causes significant overlap in phenotypic features which includes craniofacial dysmorphology, cardiac, cutaneous, musculoskeletal, GI and ocular abnormalities, and a predisposition to cancer. The proceedings from the symposium {"}Recent Developments in Neurofibromatoses (NF) and RASopathies: Management, Diagnosis and Current and Future Therapeutic Avenues{"} chronicle this timely and topical clinical translational research symposium. The overarching goal was to bring together clinicians, basic scientists, physician-scientists, advocate leaders, trainees, students and individuals with Ras pathway syndromes to discuss the most state-of-the-art basic science and clinical issues in an effort to spark collaborations directed towards the best practices and therapies for individuals with RASopathies.",
keywords = "Capillary malformation-AV malformation syndrome, Cardio-facio-cutaneous syndrome, Costello syndrome, Legius syndrome, Neurofibromatosis, Noonan syndrome, Ras/MAPK, RASopathy, Signal transduction pathway, Therapy",
author = "Rauen, {Katherine A.} and Huson, {Susan M.} and Emma Burkitt-Wright and Evans, {D. Gareth} and Said Farschtschi and Ferner, {Rosalie E.} and Gutmann, {David H.} and Hanemann, {C. Oliver} and Bronwyn Kerr and Eric Legius and Parada, {Luis F.} and Michael Patton and Juha Peltonen and Nancy Ratner and Riccardi, {Vincent M.} and {van der Vaart}, Thijs and Miikka Vikkula and Viskochil, {David H.} and Martin Zenker and Meena Upadhyaya",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/ajmg.a.36793",
language = "English (US)",
volume = "167",
pages = "1--10",
journal = "American Journal of Medical Genetics, Part A",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Recent developments in neurofibromatoses and RASopathies

T2 - Management, diagnosis and current and future therapeutic avenues

AU - Rauen, Katherine A.

AU - Huson, Susan M.

AU - Burkitt-Wright, Emma

AU - Evans, D. Gareth

AU - Farschtschi, Said

AU - Ferner, Rosalie E.

AU - Gutmann, David H.

AU - Hanemann, C. Oliver

AU - Kerr, Bronwyn

AU - Legius, Eric

AU - Parada, Luis F.

AU - Patton, Michael

AU - Peltonen, Juha

AU - Ratner, Nancy

AU - Riccardi, Vincent M.

AU - van der Vaart, Thijs

AU - Vikkula, Miikka

AU - Viskochil, David H.

AU - Zenker, Martin

AU - Upadhyaya, Meena

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Neurofibromatosis type 1 (NF1) was the first RASopathy and is now one of many RASopathies that are caused by germline mutations in genes that encode components of the Ras/mitogen-activated protein kinase (MAPK) pathway. Their common underlying pathogenetic etiology causes significant overlap in phenotypic features which includes craniofacial dysmorphology, cardiac, cutaneous, musculoskeletal, GI and ocular abnormalities, and a predisposition to cancer. The proceedings from the symposium "Recent Developments in Neurofibromatoses (NF) and RASopathies: Management, Diagnosis and Current and Future Therapeutic Avenues" chronicle this timely and topical clinical translational research symposium. The overarching goal was to bring together clinicians, basic scientists, physician-scientists, advocate leaders, trainees, students and individuals with Ras pathway syndromes to discuss the most state-of-the-art basic science and clinical issues in an effort to spark collaborations directed towards the best practices and therapies for individuals with RASopathies.

AB - Neurofibromatosis type 1 (NF1) was the first RASopathy and is now one of many RASopathies that are caused by germline mutations in genes that encode components of the Ras/mitogen-activated protein kinase (MAPK) pathway. Their common underlying pathogenetic etiology causes significant overlap in phenotypic features which includes craniofacial dysmorphology, cardiac, cutaneous, musculoskeletal, GI and ocular abnormalities, and a predisposition to cancer. The proceedings from the symposium "Recent Developments in Neurofibromatoses (NF) and RASopathies: Management, Diagnosis and Current and Future Therapeutic Avenues" chronicle this timely and topical clinical translational research symposium. The overarching goal was to bring together clinicians, basic scientists, physician-scientists, advocate leaders, trainees, students and individuals with Ras pathway syndromes to discuss the most state-of-the-art basic science and clinical issues in an effort to spark collaborations directed towards the best practices and therapies for individuals with RASopathies.

KW - Capillary malformation-AV malformation syndrome

KW - Cardio-facio-cutaneous syndrome

KW - Costello syndrome

KW - Legius syndrome

KW - Neurofibromatosis

KW - Noonan syndrome

KW - Ras/MAPK

KW - RASopathy

KW - Signal transduction pathway

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84919632825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919632825&partnerID=8YFLogxK

U2 - 10.1002/ajmg.a.36793

DO - 10.1002/ajmg.a.36793

M3 - Article

C2 - 25393061

AN - SCOPUS:84919632825

VL - 167

SP - 1

EP - 10

JO - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 1552-4825

IS - 1

ER -